Literature DB >> 22961070

Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus.

Lijun Song1, Feng Qiu, Yuchen Fan, Feng Ding, Huaxiang Liu, Qiang Shu, Weiwei Liu, Xingfu Li.   

Abstract

The aim of this study was to research the expression of IL-37 in systemic lupus erythematosus (SLE) patients and the effect of glucocorticoid on IL-37. Thirty newly diagnosed severe SLE patients receiving prednisone 1 mg/kg/day for 14 consecutive days and 30 healthy subjects were enrolled into this study. The plasma levels of IL-37 and other cytokines were detected by ELISA and the relative mRNA amounts of IL-37 and other cytokines were detected by RT-PCR. The plasma levels of IL-37, IL-18, IL-18BP, IFN-γ, and IL-6 in SLE patients increased significantly compared with healthy controls (p<0.05). The relative amount of IL-37 mRNA increased by 2.45-fold in pre-treatment SLE patients compared with controls (p<0.05). Plasma concentrations of IL-37 correlated with IL-18, IL-18BP, IFN-γ, IL-6 and SLEDAI score in both pre-treatment and post-treatment SLE patients. The plasma levels of IL-37 decreased significantly after treatment of glucocorticoid. The relative amount of IL-37 mRNA decreased by 24.5 % in post-treatment SLE patients compared with pre-treatment ones (p<0.01). In conclusion, IL-37 is upregulated in active SLE patients. IL-37 is correlated with pro-inflammatory cytokines and SLEDAI. Glucocorticoid can downregulate the expression of IL-37 and other cytokines in SLE patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961070     DOI: 10.1007/s10875-012-9791-z

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  44 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Anti-inflammatory actions of steroids: molecular mechanisms.

Authors:  P J Barnes; I Adcock
Journal:  Trends Pharmacol Sci       Date:  1993-12       Impact factor: 14.819

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes.

Authors:  A Waage; O Bakke
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

Review 5.  Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18.

Authors:  Nicola Calvani; Marco Tucci; Hanno B Richards; Paola Tartaglia; Franco Silvestris
Journal:  Autoimmun Rev       Date:  2005-11       Impact factor: 9.754

6.  Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis.

Authors:  C Plater-Zyberk; L A Joosten; M M Helsen; P Sattonnet-Roche; C Siegfried; S Alouani; F A van De Loo; P Graber; S Aloni; R Cirillo; E Lubberts; C A Dinarello; W B van Den Berg; Y Chvatchko
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

7.  IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp.

Authors:  G Pan; P Risser; W Mao; D T Baldwin; A W Zhong; E Filvaroff; D Yansura; L Lewis; C Eigenbrot; W J Henzel; R Vandlen
Journal:  Cytokine       Date:  2001-01-07       Impact factor: 3.861

8.  Interleukin-6 promoter polymorphism -174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients.

Authors:  Maria José Santos; Diana Fernandes; Susana Capela; Jose Canas da Silva; João Eurico Fonseca
Journal:  Clin Rheumatol       Date:  2010-12-14       Impact factor: 2.980

9.  MIF as a glucocorticoid-induced modulator of cytokine production.

Authors:  T Calandra; J Bernhagen; C N Metz; L A Spiegel; M Bacher; T Donnelly; A Cerami; R Bucala
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

10.  In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis.

Authors:  Ana-Maria Bulau; Michaela Fink; Christof Maucksch; Roland Kappler; Doris Mayr; Kai Wagner; Philip Bufler
Journal:  ScientificWorldJournal       Date:  2011-12-26
View more
  39 in total

1.  Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

Authors:  Jesper F Højen; Thomas A Rasmussen; Karen Lise D Andersen; Anni A Winckelmann; Rune R Laursen; Jesper D Gunst; Holger J Møller; Mayumi Fujita; Lars Østergaard; Ole S Søgaard; Charles A Dinarello; Martin Tolstrup
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

2.  Increased serum interleukin-37 (IL-37) levels correlate with oxidative stress parameters in Hashimoto's thyroiditis.

Authors:  R M Ruggeri; M Cristani; T M Vicchio; A Alibrandi; S Giovinazzo; A Saija; A Campennì; F Trimarchi; S Gangemi
Journal:  J Endocrinol Invest       Date:  2018-05-23       Impact factor: 4.256

3.  Association of interleukin 1 family with systemic sclerosis.

Authors:  Li Zhang; Jun-Wei Yan; Yu-Jie Wang; Ya-Nan Wan; Bing-Xiang Wang; Jin-Hui Tao; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

4.  Plasma levels and expression of interleukin-37 in patients with immune thrombocytopenia.

Authors:  Feng Zhang; Xiao-Juan Zhu; Xiao-Jing Zhu; Yan-Xia Liu; Ting Yuan; Qing-Min Yao
Journal:  Exp Ther Med       Date:  2019-07-30       Impact factor: 2.447

5.  Elevated plasma levels of TL1A in newly diagnosed systemic lupus erythematosus patients.

Authors:  Wang-Dong Xu; Dao-Jun Chen; Rui Li; Chun-Xia Ren; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2015-05-01       Impact factor: 2.631

Review 6.  The Role of IL-37 in Non-Cancerous Diseases.

Authors:  Vivi A Ding; Ziwen Zhu; Alyse A Mantz; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Pathol Oncol Res       Date:  2016-10-27       Impact factor: 3.201

7.  IL-37bΔ1-45 suppresses the migration and invasion of endometrial cancer cells by targeting the Rac1/NF-κB/MMP2 signal pathway.

Authors:  Xishuang Wang; Zengtao Wei; Zhongyun Tang; Chenyue Xue; Huayun Yu; Derui Zhang; Yulan Li; Xihong Liu; Yongyu Shi; Lining Zhang; Guoling Chen; Huaiyu Zhou; Jianing Wang; Xiaoyan Wang
Journal:  Lab Invest       Date:  2021-03-22       Impact factor: 5.662

8.  Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy.

Authors:  Lijuan Wang; Yanchun Quan; Yongfang Yue; Xueyuan Heng; Fengyuan Che
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

Review 9.  Suppression of innate inflammation and immunity by interleukin-37.

Authors:  Charles A Dinarello; Claudia Nold-Petry; Marcel Nold; Mayumi Fujita; Suzhao Li; Soohyun Kim; Philip Bufler
Journal:  Eur J Immunol       Date:  2016-05       Impact factor: 5.532

Review 10.  Overview of the IL-1 family in innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.